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SUMMARY
The safety of long-term prophylactic antiarrhythmic therapy with procaine amide was studied in 78 patients recovering from acute myocardial infarction. Patients were randomly allocated to a control or treatment group The control and study groups each consisted of 39 patients with 31 males and eight females. The mean age of the former group was 59.7 ± 12.7 years while the mean of the later was 56.2 ± 11.5 years. Twentyeight patients in each group experienced transmural infarction. In 17 of the control group and 15 of the treated group, the infarction was located anteriorly. Ten control and seven treated patients exhibited paroxysms of ventricular tachycardia while in the CCU. Left ventricular failure manifested by rales at the lung bases and an S3 gallop was observed early in the hospital course in 15 of the control and 12 of the study groups.
Results

Treatment Group
Early reactions forcing discontinuation of procaine amide within the first 3 weeks involved nine of the 39 patients. Five had unexplained fevers occurring 2-18 days after the start of treatment. Two patients developed rashes in their first week of therapy and one each had postural hypotension and headaches. In four cases, the patient was rechallenged with the drug and in each, the symptoms recurred. The ANA titers did not rise in any of these nine patients. Three patients without symptoms voluntarily discontinued the drug during the first 3 months. One man died suddenly 6 weeks postinfarction while on therapy.
Late reactions were observed in 14 of 26 patients who took procaine amide for 3 months or longer. Of these, 12 had arthralgia and/or rash, one had headaches, and another marked fatigue. Four patients without symptoms voluntarily stopped the medication after 6-22 months of therapy. Eight patients continued to take procaine amide for 18-30 months without adverse effects (table 1). 21 10 Procaine amide D/C In the present study, procaine amide was selected as the antiarrhythmic agent. It has been demonstrated to be highly effective in suppressing ventricular arrhythmias both clinically and experimentally12-14 Although it is known to provoke a lupus erythematosuslike syndrome,'18 the incidence of this reaction has not been documented in any large prospective study. Procaine amide-induced lupus is not known to be fatal, and the complication has been consistently reversible. Other adverse effects have been relatively uncommon.19 ' 20 We rejected the use of quinidine as a prophylactic measure against sudden death because of the high frequency of side effects and even death which attend its use. Toxic reactions include gastrointestinal derangements, hematologic disorders, syncope, and major arrhythmias. Rossi In the present study, it was demonstrated that prolonged oral administration of procaine amide resulted in a high incidence of adverse reactions. Twenty-three per cent of patients were forced to discontinue therapy within the first month. Symptoms occurred in 54% of those taking the drug for longer than 3 months. Most of these patients had a lupus-type syndrome. However, in all instances, symptoms subsided after discontinuation of procaine amide, and deranged serologic values returned toward normal. The elevated ANA titers and positive LE preparations were not associated with other abnormalities in plasma protein fractions which reflect changes in the immunologic process, hepatic protein synthesis, and the presence of inflammatory reactions.
The dose of procaine amide that was administered in the present study is now known to be inadequate for optimal therapeutic effect.27 Nevertheless monitoring revealed a reduction in incidence of major ventricular arrhythmias. While six of 23 monitored-control patients demonstrated couplets and ventricular tachycardia, this was observed in only one of 21 control subjects. There was a parallel effect on mortality; while four of 39 controls died suddenly, only one of 27 in the treatment group who continued to take the drug was similarly afflicted. These findings did not reach statistical significance at the 5% level. No differences were noted in the occurrence of lesser arrhythmias such as occasional or frequent premature ventricular beats. An effect on major but not upon minor arrhythmias was also observed in an animal experimental study in our laboratory (Yenikonshian S, Kosowsky BD, Lown B: Unpublished data). Awake dogs were subjected to acute coronary closure by means of an inflatable balloon which had been implanted around the left anterior descending coronary artery. In untreated animals, 72% developed ventricular fibrillation during or immediately following a 10-min occlusion. Pretreatment with procaine amide reduced the incidence o f ventricular fibrillation to 17% (P <0.05). However, there was no significant difference in the incidence of VPB's between the two groups. In the treated animals ventricular arrhythmias, although present, did not degenerate into fibrillation.
The high incidence of toxicity precludes the longterm prophylactic use of procaine amide in a CHD population. More 
